GlassScriptPhysician profile
Satyaki Banerjee
NPI 1790815926
$259,888.76
in general payments reported to CMS, 2019-2025
51 companies · $19K in 2025
The $19K reported for 2025 was more than what 97% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $22K · 2021: $24K · 2022: $73K · 2023: $84K · 2024: $24K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $52K · Consulting Fee: $30K · Travel and Lodging: $25K · Long Term Medical Supply Or Device Loan: $14K · Food and Beverage: $6,070 · Honoraria: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $52,380.00 |
| Consulting Fee | $29,796.00 |
| Travel and Lodging | $24,503.20 |
| Long Term Medical Supply Or Device Loan | $14,400.00 |
| Food and Beverage | $6,069.74 |
| Honoraria | $400.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $168,668.67 | 2021-2025 | Argyle, Palindrome, Ellipsys Vascular Access System |
| Angiodynamics, INC. | $23,552.00 | 2021-2025 | Venacure 1470 Pro, Auryon Laser System 100-120 Vac |
| W. L. Gore & Associates, INC. | $21,886.31 | 2019-2024 | Gore Viabahn Endoprosthesis |
| Mozarc Medical US LLC | $19,122.19 | 2023-2025 | Argyle, Palindrome, Chameleon |
| Covidien LP | $11,319.29 | 2019-2020 | |
| Cordis US Corp. | $6,014.63 | 2021-2024 | Saber, Mynx Control |
| Bard Peripheral Vascular, INC. | $2,756.32 | 2019-2025 | Pristine, Covera, Set Aspirex S 10f 110cm |
| Medtronic Vascular, INC. | $985.37 | 2019-2020 | |
| Boston Scientific Corporation | $892.39 | 2021-2025 | Varithena Administration Pack |
| Nxstage Medical, INC. | $524.92 | 2021-2022 | |
| Vifor Pharma, INC. | $504.79 | 2019-2024 | Veltassa, Korsuva |
| Daiichi Sankyo INC. | $471.14 | 2019-2024 | Injectafer |
| Astrazeneca Pharmaceuticals LP | $412.33 | 2019-2024 | Farxiga, Lokelma |
| Merit Medical Systems INC | $350.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $299.65 | 2019-2024 | Jynarque |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satyaki Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.